MedImmune and Humabs have reasons to be happy. Their candidate for an Influenza A vaccine has made it into well-known journal, Cell, boasting a unique affinity to the virus with multiple mechanisms to stop infection.
The promising candidate is MEDI8852, an antibody initially developed by Humabs (Switzerland). It targets Influenza A virus (the group of viruses known as avian flu), which is responsible for most influenza hospitalizations and has had health authorities concerned about a possible pandemic.
MEDI8852 was the result of Humab’s platform to use human memory B-cells from patients that recovered from infectious diseases and isolate their ‘winner antibodies’. Besides Influenza, this strategy also yielded results against cytomegalovirus, Middle East Respiratory Syndrome (MERS) and Ebola.